ClinicalTrials.gg
CompletedNCT00829673Updated Aug 19, 2024Results posted

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

A Phase 1 interventional study of Dexmethylphenidate Hydrochloride and Dexmethylphenidate Hydrochloride in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the commercially available dexmethylphenidate hydrochloride (Focalin®, Novartis Pharmaceuticals Corporation) in a test population of 24 adult subjects under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex: Male and Female; similar proportion of each preferred.
  2. Age: At least 18 years.
  3. Weight: (Body Mass Index) less than or equal to 30.
  4. Qualifying subjects must be in good health and physical condition as determined by medical history, complete physical examination, and laboratory tests, all obtained within four (4) weeks prior to study start. The subjects may not have a history of significant past illness expected to affect the investigation. The normal status of subjects will be confirmed by the following procedures:

    • Laboratory Tests: , hematocrit, RBC, WBC, differential count, serum electrolytes (Na, K, Cl), fasting blood glucose, BUN, ,m creatinine, , ALT, LD, alkaline phosphatase and urinalysis. , , , breath alcohol test, and drugs of abuse testing will be done for screening purposes only. Urine drugs of abuse testing and breath alcohol testing will be repeated at each check-in. Female subjects will have a serum pregnancy test done at screening and a urine pregnancy test prior to each study period at check-in.

    Laboratory values which are greater than ±20% of the normal range will not qualify unless specifically accepted (with comment) by the Principal Investigator. Results of HIV, Hepatitis B, Hepatitis C, and drugs of abuse must be negative or non-reactive for the subject to qualify for the study.

    • : A 12-lead electrocardiogram (ECG) will be obtained for all subjects. The original tracings, plus interpretation, will be included in the case report form packet.
  5. Subjects must read and sign the Consent Form.

Exclusion criteria

Exclusion Criteria

  1. Subjects not complying with the above inclusion criteria must be excluded from the study.
  2. In addition, any one of the conditions listed below will exclude a subject from the study:

    • History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
    • History of , stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
    • History of GERD (gastroesophageal reflux disease), stricture of the esophagus, achalasia, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
    • History of upper gastrointestinal disorder such as dysphagia, esophagitis, gastritis, ulcers.
    • History of treatment for asthma within the past five (5) years.
    • History of marked treatable anxiety, tension, agitation.
    • History of glaucoma
    • History of motor tics
    • Family history or diagnosis of tourettes syndrome
    • History of treatment with monoamine oxidase inhibitors
    • History of seizures
    • Inability to sit upright for a period of at least 30 minutes
    • Females who are pregnant or lactating
    • History of to dexmethylphenidate hydrochloride, methylphenidate or any central nervous system stimulant
  3. Conditions upon screening which might contraindicate or require that caution be used in the administration of dexmethylphenidate hydrochloride, including:

    • Sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm Hg.
    • Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.
  4. Inability to read and/or sign the consent form.
  5. Treatment with any other drug during the four (4) weeks prior to the initial dosing for this study.
  6. Subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.
  7. Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.). Three (3) months abstinence is required.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: Dexmethylphenidate Hydrochloride

  • Active comparator
    2

    Focalin®

    Drug: Dexmethylphenidate Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration)

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 16 hour period.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 16 hour period.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 16 hour period.

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneDexmethylphenidate HCl FirstFocalin® First
Started1212
Completed1212
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneDexmethylphenidate HCl FirstFocalin® First
Started1212
Completed1112
Not completed10
Withdrew: Withdrawal by subject10
Second Intervention
Participant flow — Second Intervention
MilestoneDexmethylphenidate HCl FirstFocalin® First
Started1112
Completed1112
Not completed00

Outcome measures

PrimaryCmax (Maximum Observed Concentration)

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 16 hour period.
Reported as:
Mean · pg/mL
Cmax (Maximum Observed Concentration)
pg/mLDexmethylphenidate HClFocalin®
Cmax (Maximum Observed Concentration)15668.17 ± 5081.4814526.09 ± 4639.79
Statistical analysis
  • Dexmethylphenidate HCl vs Focalin® · Ratio of the t/r geometric mean x 100: 107.82 · 90% CI 100.24 to 115.98Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 16 hour period.
Reported as:
Mean · pg*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
pg*h/mLDexmethylphenidate HClFocalin®
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)81531.55 ± 40876.9679972.63 ± 35905.93
Statistical analysis
  • Dexmethylphenidate HCl vs Focalin® · Ratio of the t/r geometric mean x 100: 100.74 · 90% CI 97.3 to 104.29Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 16 hour period.
Reported as:
Mean · pg*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
pg*h/mLDexmethylphenidate HClFocalin®
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)86046.67 ± 49869.6884376.75 ± 43435.19
Statistical analysis
  • Dexmethylphenidate HCl vs Focalin® · Ratio of the t/r geometric mean x 100: 100.5 · 90% CI 97.09 to 104.03Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dexmethylphenidate HCl FirstFocalin® FirstTotal
<=18 years000
Between 18 and 65 years121224
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Dexmethylphenidate HCl FirstFocalin® FirstTotal
Female156
Male11718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dexmethylphenidate HCl FirstFocalin® FirstTotal
Black268
White10616
Region of Enrollment
Region of Enrollment(participants)Dexmethylphenidate HCl FirstFocalin® FirstTotal
United States121224
08

Study locations

1 site
  • Gateway Medical Research, Inc.
    Saint Charles, Missouri 63301, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Jun 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 27, 2009
Start
Jun 2004
Primary completionActual
Jun 2004
CompletionActual
Jun 2004
Results first posted
Aug 4, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00829673
First posted
Jan 27, 2009
Start date
Jun 2004
Primary completion
Jun 2004
Completion
Jun 2004
Results posted
Aug 4, 2009
Last update
Aug 19, 2024

Study contacts

Irwin Plisco, M.D.
principal investigator · Cetero Research, San Antonio

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion